Stockscreener 앱 받기
7.83
0.51%
-0.04
시간 외 거래:
7.83
Amneal Pharmaceuticals Inc 주식(AMRX)의 최신 뉴스
Amneal gains FDA approval for dementia and oncology drugs - MSN
Amneal Pharmaceuticals (AMRX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Amneal Launches Mesalamine and Receives FDA Approval for Lenalidomide - Pharmacy Practice News
AMRXAmneal Pharmaceuticals Inc Latest Stock News & Market Updates - StockTitan
Amneal Launches Mesalamine And Receives U.S. FDA Approval For Lenalidomide - Marketscreener.com
Amneal Pharmaceuticals Launching Mesalamine, Gets US FDA Approval for Lenalidomide - Marketscreener.com
Amneal introduces ulcerative colitis drug, plans future launch - Investing.com India
Amneal introduces ulcerative colitis drug, plans future launch By Investing.com - Investing.com Nigeria
Double Win for Amneal: Taps Into $147M Market Today, Secures Future Growth with New FDA Approval - StockTitan
Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest - Yahoo Finance
There's No Escaping Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Muted Revenues - Simply Wall St
32,757 Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Bought by Entropy Technologies LP - MarketBeat
Amneal Pharmaceuticals : Expiration Dates for Certain Lots of Generic Adrenaclick® Epinephrine Injection, USP Auto-Injector Extended to 20 Months - Marketscreener.com
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Down 18.0% in January - MarketBeat
Stonebridge Financial Group LLC Buys Shares of 36,054 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Although Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) insiders have sold lately, they have the highest ownership with 51% stake - Yahoo Finance
Amneal Pharmaceuticals Launches FOCINVEZ: A Game-Changer In Ready-To-Use Antiemetic Injectable Formulations... - WhaTech
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Gautam Patel Sells 80,000 Shares - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $10.00 Consensus Target Price from Brokerages - MarketBeat
China Universal Asset Management Co. Ltd. Purchases Shares of 65,698 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Drug Cos. Urge Full Fed. Circ. To Hear Teva Orange Book Row - Law360
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report? - MSN
Amneal Pharmaceuticals Director Sells 80,000 Shares - TradingView
Amneal Pharmaceuticals' SWOT analysis: generic drug maker's stock poised for growth - Investing.com Canada
Wall Street Analysts Predict a 27.12% Upside in Amneal (AMRX): Here's What You Should Know - MSN
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol - Yahoo Finance
Short Interest in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Declines By 6.8% - MarketBeat
Epinephrine Autoinjector Market to Grow by USD 2.44 Billion (2024-2028), Rising Allergy Prevalence Boosts Growth, with AI Powering Market EvolutionTechnavio - The Malaysian Reserve
SG Americas Securities LLC Has $590,000 Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Amneal Says US FDA Accepts New-Drug Application for IPX203 to Treat Parkinson's Disease; Shares Rise - Marketscreener.com
Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025 - BioSpace
Amneal Sets Key Q4 2024 Earnings DateMark Your Calendar for Major Pharma Update - StockTitan
Amneal Celebrates FDA Approvals For Generic Namzaric And Afinitor Disperz - News & Insights
Is Teva-Amneal Inhaler Case A Double-Edged Sword For The Generics Industry? - Citeline News & Insights
Amneal Pharmaceuticals (NASDAQ:AMRX) Trading Up 5.2%Time to Buy? - MarketBeat
Premature Ejaculation Treatment Market to Grow by USD 1.53 Billion (2025-2029), Off-Label Drug Efficacy Boosts Revenue, Report with AI-Powered InsightsTechnavio - The Malaysian Reserve
Amneal Pharmaceuticals Gets FDA Approval for Alzheimer's Treatment and Brain Tumor Drug - MarketWatch
Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin - BioSpace
Amneal gains FDA approval for dementia and oncology drugs By Investing.com - Investing.com Australia
Amneal gets FDA approval for generic Byetta, resubmits DHE NDA - MSN
Assenagon Asset Management S.A. Decreases Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Assenagon Asset Management S.A. Trims Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Update - MarketBeat
Hennessy Advisors Inc. Acquires 106,600 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Is Targeting 70% Of Untapped Biologics In The ‘Golden Era’ Of Biosimilars - Citeline News & Insights
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year? - MSN
3.23%
3.94%
자본화:
|
볼륨(24시간):